![Thomas Ulmer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Ulmer
Director of Finance/CFO at
PYC THERAPEUTICS LIMITED
Profile
Mr. Thomas Ulmer is a Chief Financial Officer at PYC Therapeutics Ltd. He is on the Board of Directors at Aravax Pty Ltd. Mr. Ulmer was previously employed as a Co-Managing Director by Immatics Biotechnologies GmbH, a Head-Planning, Forecasting & Resource Allocation by Merck KGaA, a Chief Financial Officer by Cell Therapies Pty Ltd., and a Chief Financial Officer by Immatics NV.
He received his MBA from the University of Giessen.
Thomas Ulmer active positions
| Companies | Position | Start |
|---|---|---|
| PYC THERAPEUTICS LIMITED | Director of Finance/CFO | 07/07/2026 |
Aravax Pty Ltd.
 Aravax Pty Ltd. BiotechnologyHealth Technology Develops treatments for peanut allergies | Director/Board Member | 01/11/2020 |
Former positions of Thomas Ulmer
| Companies | Position | End |
|---|---|---|
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Chief Executive Officer | 12/02/2020 |
| MERCK KGAA | Corporate Officer/Principal | 01/07/2016 |
Cell Therapies Pty Ltd. | Director of Finance/CFO | - |
| IMMATICS N.V. | Director of Finance/CFO | - |
Training of Thomas Ulmer
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
59
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
PYC Therapeutics Ltd.
 PYC Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Provides discovery and development of peptide based therapeutic candidates | Health Technology |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
University of Giessen
 University of Giessen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cell Therapies Pty Ltd. | |
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Develops treatments for peanut allergies | Health Technology |
Immatics NV
 Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
- Stock Market
- Insiders
- Thomas Ulmer
